Unraveling elements of value-based pricing from a pharmaceutical industry’s perspective: a scoping review

Autor: Aniek Dane, Carin Uyl-de Groot, Hugo van der Kuy

Publikováno v: Frontiers in Pharmacology, Vol 15 (2024)

Health authorities use value-based pricing models to determine the value of innovative drugs and to establish a price. Pharmaceutical companies prefer value-based pricing over cost-based pricing. It is ambiguous whether value-based pricing has the sa

Externí odkaz: https://doaj.org/article/0f3107b91e954dd98473a59dfca9b17b

Hospital-based or home-based administration of oncology drugs? A micro-costing study comparing healthcare and societal costs of hospital-based and home-based subcutaneous administration of trastuzumab

Autor: Margreet Franken, Tim Kanters, Jules Coenen, Paul de Jong, Agnes Jager, Carin Uyl-de Groot

Publikováno v: Breast, Vol 52, Iss , Pp 71-77 (2020)

Objective: To investigate resource use and time investments of healthcare professionals, patients and their family and to compare healthcare and societal costs of one single hospital-based and one single home-based subcutaneous administration of tras

Externí odkaz: https://doaj.org/article/378c22a1cf204eddb4e0a3d82c504364

Legitimacy as Social Infrastructure: a Critical Interpretive Synthesis (Preprint)

Autor: Sydney Evelyn Howe, Carin Uyl-de Groot, Rik Wehrens

UNSTRUCTURED As technology is integrated into healthcare delivery, questions related to the adoption and acceptance of these new technologies become increasingly urgent. Current models of technology adoption/acceptance of health technologies leave la

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0823075cebed263099d86c758a5aefe1
https://doi.org/10.2196/preprints.48955

Costs of Newly Funded Proton Therapy Using Time-Driven Activity-Based Costing in The Netherlands

Autor: Yi Hsuan Chen, Hedwig M. Blommestein, Reinder Klazenga, Carin Uyl-de Groot, Marco van Vulpen

Publikováno v: Chen, Y H, Blommestein, H M, Klazenga, R, Uyl-de Groot, C & van Vulpen, M 2023, ' Costs of Newly Funded Proton Therapy Using Time-Driven Activity-Based Costing in The Netherlands ', Cancers, vol. 15, no. 2, 516 . https://doi.org/10.3390/cancers15020516
Cancers; Volume 15; Issue 2; Pages: 516
Cancers, 15(2):516. Multidisciplinary Digital Publishing Institute (MDPI)

Background: Proton therapy (PT) has characteristics that enable the sparing of healthy, non-cancerous tissue surrounding the radiotherapy target volume better from radiation doses than conventional radiotherapy for patients with cancer. While this in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8f4cb0001cdee2ea1f733fd09728468
https://research.vumc.nl/en/publications/910e91e4-d60f-4f28-954b-1097190ba59b

Abstract P2-08-02: Trends in survival and the introduction of novel systemic therapies for locoregional and metastatic breast cancer in the Netherlands, 1989-2017

Autor: Sabine Siesling, Otto Visser, Carin Uyl-de Groot, Hedwig M. Blommestein, Marianne Luyendijk

Publikováno v: Cancer Research. 80:P2-08

Objective:The introduction of innovations in breast cancer care such as screening and new systemic treatments may influence the proportions of patients with metastatic and locoregional disease as well as their survival outcomes. Aim of this study is

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::73a7300d8a428481b6685a9d1db65d59
https://doi.org/10.1158/1538-7445.sabcs19-p2-08-02